Available from: go.gov.sg/acg-initiating-basal-insulin-in-type-2-diabetes-mellitus The Ministry of Health, Singapore disclaims any and all liability to any party for any direct, indirect, implied, punitive or other consequential damages arising directly or indirectly from any use of this ACG, which is provided as is, without warranties.
Dose-by-dose weight loss in Phase 2 (NEJM) Phase 2 NEJM weight loss by dose, 24 and 48 weeks Dose 1 mg 24 weeks -7.2% 48 weeks -8.7% Dose 4 mg 24 weeks -12.9% 48 weeks -17.5% Dose 8 mg 24 weeks -15.7% 48 weeks -22.8% Dose 12 mg 24 weeks -17.5% 48 weeks -24.2% Dose Placebo 24 weeks -1.6% 48 weeks -2.1% Source: Jastreboff et al., NEJM 2023
The documented concern categories include: claims implying compounded GLP-1 products are equivalent to FDA-approved drugs
They should also be kept out of reach of children
Glutathione GSH concentration in blood increased after absorption from the orobuccal mucosa, the change being statistically significant compared to basal levels